English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 62569/95226 (66%)
造訪人次 : 2515318      線上人數 : 232
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/41572

    題名: Sarcosine (N-methylglycine) or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study
    作者: Lane, Hsien-Yuan;Liu, Yi-Ching;Huang, Chieh-Liang;Chang, Yue-cune;Liau, Chun-Hui;Perng, Cheng-Hwang;Tsai, Guochuan E.
    貢獻者: 淡江大學數學學系
    關鍵詞: Glutamate;GlyT-1;N-methyl-D-aspartate;sarcosine;schizophrenia
    日期: 2005-11-01
    上傳時間: 2010-01-28 07:51:26 (UTC+8)
    出版者: American Medical Association
    摘要: Background: Small molecules that enhance the N-methyl-D-aspartate (NMDA) neurotransmission have been shown to be beneficial as adjuvant therapy for schizophrenia. Among these compounds, sarcosine (a glycine transporter-I inhibitor), when added to an existing regimen of antipsychotic drugs, has shown its efficacy for both chronically stable and acutely ill patients. However, the efficacy of these agents as a primary antipsychotic agent has not yet been demonstrated. Methods: Twenty acutely symptomatic drug-free patients with schizophrenia were randomly assigned under double-blind conditions to receive a 6-week trial of 2 g or 1 g of sarcosine daily. Results: Overall, patients in the 2-g group were more likely to respond as defined by a 20% or more reduction of the Positive and Negative Syndrome Scale total score, particularly among antipsychotic-naïve patients. However, there was no significant between-group difference in the sarcosine dose time interaction analysis. Both doses were well tolerated with minimal side effects. Conclusions: Although patients receiving the 2-g daily dose were more likely to respond, it requires further clarification whether the effect is limited to the antipsychotic-naive population. Future placebo- or active-controlled, larger-sized studies are needed to fully assess sarcosine’s effects.
    關聯: Archives of General Psychiatry 62, pp.1196-1204
    DOI: 10.1001/archpsyc.62.11.1196
    顯示於類別:[數學學系暨研究所] 期刊論文


    檔案 描述 大小格式瀏覽次數
    0006-3223_63(1)p9-12.pdf84KbAdobe PDF3檢視/開啟



    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - 回饋